nanobiotechnology-2018-scientifictracks

4 / 18

Nanobiotechnology 2018
Page 22
Nano Research & Applications
ISSN: 2471-9838
E u r o S c i C o n C o n f e r e n c e o n
Nanotech & Nanobiotechnology
J u l y 1 2 - 1 3 , 2 0 1 8
P a r i s , F r a n c e
In this talk, I will first briefly discuss the general strategies and integrated
computational-experimental approaches used to understand the detailed
molecular mechanisms of increasingly complex biological systems (such as
those related to cancers, HIV virus, neurodegenerative diseases, inflammation,
cardiovascular diseases, and drug addiction) and perform mechanism-based
design, discovery, and development of novel drugs including nanoparticles.
I will also discuss the general trend of rational drug design and discovery
through specific examples of our integrated efforts from understanding
molecular mechanism to clinical development. The presentation will show how
powerful understanding the detailed molecular mechanism and mechanism-
based computational design are in the current drug design, discovery, and
development. The integrated computational-experimental approaches are of
great value not only for small-molecule drug discovery, but also for discovery
and development of novel, therapeutically promising nanoparticles. Integrated
computational-experimental drug design and discovery efforts have led to
exciting discovery of promising drug candidates, including our designed novel
drugs in Phase II clinical trials; one has received the Breakthrough Therapy
Designation by the FDA.
Biography
Chang-Guo Zhan is an Endowed Professor of Pharmaceutical
Sciences and Director of Molecular Modeling and
BiopharmaceuticalCenter intheCollegeofPharmacy,University
of Kentucky. He also serves as Director of Chemoinformatics
and Drug Design Core of the Center for Pharmaceutical
Research and Innovation at the University of Kentucky. His lab
has successfully designed and discovered several promising
therapeutic candidates, including two in Phase II clinical trials;
one has received the Breakthrough Therapy Designation by
the FDA. He is a winner of 2005 Emerging Computational
Technology Prize, American Chemical Society (ACS) Division
of Computers in Chemistry and is the current recipient of the
NIDA Translational Avant-Garde Award from the NIH. He was
elected AAPS Fellow in 2010 and won 2016 AAPS Research
Achievement Award in Drug Discovery and Development
Interface. He is also a UK Chapter Inductee of the National
Academy of Inventors (NAI).
,
Structure and mechanism-based design of nanoparticles as
therapeutic candidates
Chang-Guo Zhan and Fang Zheng
University of Kentucky, USA
Chang-Guo Zhan et al., Nano Res Appl 2018, Volume 4
DOI: 10.21767/2471-9838-C2-011